Hepatocellular Carcinoma

Drug Name: Imjudo Active Ingredient: tremelimumab Indications: To treat unresectable hepatocellular carcinoma Approval Date: 10/21/2022 Company: AstraZeneca Pharmaceuticals LP Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf